Skip to main content
. 2019 Mar 15;10:157. doi: 10.3389/fendo.2019.00157

Figure 3.

Figure 3

DHA inhibits LPS-induced bone resorption via GPR120 activation in vivo. (A) Micro-CT reconstruction images of calvariae. Images of calvariae resected from mice after 5 days of daily supracalvarial administration of PBS, LPS (100 μg/day), LPS (100 μg/day)+DHA (100 μg/day), LPS (100 μg/day)+DHA (100 μg/day)+AH7614 (100 μg/day), or DHA (100 μg/day). Arrows indicate bone resorption areas and red areas indicate extensive bone resorption. (B) Ratio of bone resorption area to total bone area. Results are expressed as means ± SD (n = 4; **p < 0.01, *p < 0.05). Differences were determined by Scheffe's test. (C) Serum CTX levels in vivo. Serum was prepared from mice following 5 days of daily supracalvarial administration of PBS, LPS (100 μg/day), LPS (100 μg/day)+DHA (100 μg/day), LPS (100 μg/day)+DHA (100 μg/day)+AH7614 (100 μg/day), or DHA (100 μg/day). Enzyme-linked immunosorbent assays was performed to determine concentrations of circulating CTX. Data are shown as means ± SD (n = 4; **p < 0.01, *p < 0.05). Differences were determined by one-way ANOVA and Turkey-Kramer tests.